MedPath

Reduction of Fluoroscopy Exposure During Atrial Fibrillation Ablation

Not Applicable
Completed
Conditions
Atrial Fibrillation
Interventions
Device: Radio-frequency catheter ablation
Registration Number
NCT02137798
Lead Sponsor
Technische Universität Dresden
Brief Summary

To evaluate reduction of fluoroscopy time/dosis and safety of atrial fibrillation ablation in patients with paroxysmal atrial fibrillation using fluoroscopy image integrated 3-dimentional electroanatomical mapping system, comparing to using 3-dimentional electroanatomical mapping system without fluoroscopy image integration

Detailed Description

The novel fluoroscopic image integrated 3-dimentional electroanatomical mapping system is designed for minimizing the exposure to X-ray for physician, staff and patients. This randomized single-center study is to evaluate the reduction on fluoroscopy levels (time and dosis) in catheter interventional treatment of symptomatic, antiarrhythmic refractory paroxysmal atrial fibrillation using fluoroscopic image integrated 3-dimentional electroanatomical mapping system, comparing with using 3-dimentional electroanatomical mapping system without fluoroscopic image integration. Patients with documented paroxysmal atrial fibrillation, who are going to receive a catheter interventional treatment to atrial fibrillation, will be randomized (1:1) into two groups after signing an informed consent. Group 1 (CARTOUNIVU): using fluoroscopic image integrated 3-dimentional electroanatomical mapping system. Group 2 (CARTO3): using 3-dimentional electroanatomical mapping system without fluoroscopic image integration.

The ablation strategies in both study groups are the same, including circumferential isolation of ipsilateral pulmonary veins (PV) and voltage map guided substrate modification. According to the randomization, the ablation procedure will be performed with or without fluoroscopic image integration.

The primary endpoint of this study is the evaluation of reduction on fluoroscopy levels (fluoroscopy time and dosis) during atrial fibrillation ablation procedure. Secondary endpoints include complete isolation of the pulmonary veins, completely bidirectional block of linear ablation lines, total procedure time, ablation-related complications.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • documented atrial fibrillation in the 12-lead ECG or Holter ECG
  • Paroxysmal symptomatic atrial fibrillation
  • Ineffectiveness of antiarrhythmic medication ( at least 1 medication )
  • Age 18-75 years
  • left atrial diameter <60 mm ( Transesophageal Echocardiography, parasternal )
  • A signed consent form
Exclusion Criteria
  • Reversible etiology of atrial fibrillation
  • Pregnancy
  • Women of childbearing potential without a negative pregnancy test within 48 hours prior to the ablation procedure
  • Intracardiac thrombus
  • Contraindication to anticoagulation
  • Thromboembolic event in the last 6 months
  • Previous left atrial ablation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CARTOUNIVURadio-frequency catheter ablationRadiofrequency catheter ablation of atrial fibrillation will be performed using fluoroscopy image integrated 3-dimentional electroanatomical mapping system
CARTO3Radio-frequency catheter ablationRadiofrequency catheter ablation of atrial fibrillation will be performed using 3-dimentional electroanatomical mapping system without fluoroscopy image integration technique
Primary Outcome Measures
NameTimeMethod
Fluoroscopy time for each step of atrial fibrillation ablation procedure1 day ( at the end of each step of atrial fibrillation ablation procedure)

Fluoroscopy time will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.

Fluoroscopy doses for each step of atrial fibrillation ablation procedure1 day ( at the end of each step of atrial fibrillation ablation procedure)

Fluoroscopy doses will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.

Secondary Outcome Measures
NameTimeMethod
Number of patients with adverse events as a measure of safetyAll patients will be followed for the duration of hospital stay for acute complications, an expected average of 3 days.

Perforation, tamponed, phrenic nerve injury and oesophagus injury (patients will be screened for oesophagus injury for a month after atrial fibrillation ablation), etc.

Total time of atrial fibrillation ablation procedure as a measure of efficacyup to 24 hours

procedure time (minute)

Number of patients with a failure of reaching endpoints of procedure as a measure of efficacy1 day ( at the end of each step of atrial fibrillation ablation procedure)

number of pulmonary veins/linear ablation lines has not been completely isolated/blocked at the end of the AF ablation

Trial Locations

Locations (1)

Department of Electrophysiology, University of Dresden - Heart Center

🇩🇪

Dresden, Saxony, Germany

© Copyright 2025. All Rights Reserved by MedPath